BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX: DDD) announced the initiation of the third of three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to complete the trial in late 2008. If approved, the Company believes its ibuprofen product would be the first and only OTC 12-hour, extended-release ibuprofen product on the market in the United States. Ibuprofen is an analgesic that is sold in immediate-dose products as Advil® and Motrin®, among others, as well as generically.
